Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

PURPOSE: The Adjuvant Paclitaxel and Trastuzumab trial was designed to address treatment of patients with small human epidermal growth factor receptor 2 (HER2)–positive breast cancer. The primary analysis of the Adjuvant Paclitaxel and Trastuzumab trial demonstrated a 3-year disease-free survival (D...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Tolaney, Sara M., Guo, Hao, Pernas, Sonia, Barry, William T., Dillon, Deborah A., Ritterhouse, Lauren, Schneider, Bryan P., Shen, Fei, Fuhrman, Kit, Baltay, Michele, Dang, Chau T., Yardley, Denise A., Moy, Beverly, Marcom, P. Kelly, Albain, Kathy S., Rugo, Hope S., Ellis, Mathew J., Shapira, Iuliana, Wolff, Antonio C., Carey, Lisa A., Overmoyer, Beth, Partridge, Ann H., Hudis, Clifford A., Krop, Ian E., Burstein, Harold J., Winer, Eric P.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2019
Matèries:
RAPID COMMUNICATION
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7587424/
https://ncbi.nlm.nih.gov/pubmed/30939096
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00066
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars